Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Apollomics Inc. (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to addre...
HC Wainwright & Co. analyst Robert Burns maintains Apollomics (NASDAQ:APLM) with a Buy and lowers the price target from ...
Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand ...
- SEC Filing
EF Hutton analyst Michael King maintains Apollomics (NASDAQ:APLM) with a Buy and lowers the price target from $11 to $6.5.
HC Wainwright & Co. analyst Robert Burns maintains Apollomics (NASDAQ:APLM) with a Buy and lowers the price target from ...
Apollomics (NASDAQ:APLM) reported quarterly losses of $(2.32) per share. This is a 72.51 percent increase over losses of $(8.44...
